EP2364154A4 - Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions - Google Patents

Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions

Info

Publication number
EP2364154A4
EP2364154A4 EP09822743.2A EP09822743A EP2364154A4 EP 2364154 A4 EP2364154 A4 EP 2364154A4 EP 09822743 A EP09822743 A EP 09822743A EP 2364154 A4 EP2364154 A4 EP 2364154A4
Authority
EP
European Patent Office
Prior art keywords
mmp9
compositions
methods
matrix metalloproteinase
mediated conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09822743.2A
Other languages
German (de)
French (fr)
Other versions
EP2364154A1 (en
Inventor
Richard L Watson
Anthony B Wood
Gregory J Archambeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microdiffusion Inc
Original Assignee
Microdiffusion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/258,210 external-priority patent/US20090274730A1/en
Application filed by Microdiffusion Inc filed Critical Microdiffusion Inc
Publication of EP2364154A1 publication Critical patent/EP2364154A1/en
Publication of EP2364154A4 publication Critical patent/EP2364154A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
EP09822743.2A 2008-10-22 2009-10-22 Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions Withdrawn EP2364154A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10745308P 2008-10-22 2008-10-22
US10748008P 2008-10-22 2008-10-22
US12/258,210 US20090274730A1 (en) 2007-10-25 2008-10-24 Compositions and methods for treating inflammation
PCT/US2009/061744 WO2010048455A1 (en) 2008-10-22 2009-10-22 Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions

Publications (2)

Publication Number Publication Date
EP2364154A1 EP2364154A1 (en) 2011-09-14
EP2364154A4 true EP2364154A4 (en) 2013-07-10

Family

ID=42119683

Family Applications (2)

Application Number Title Priority Date Filing Date
EP09822721.8A Withdrawn EP2350263A4 (en) 2008-10-22 2009-10-22 Compositions and methods for treating thymic stromal lymphopoietin (tslp)-mediated conditions
EP09822743.2A Withdrawn EP2364154A4 (en) 2008-10-22 2009-10-22 Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP09822721.8A Withdrawn EP2350263A4 (en) 2008-10-22 2009-10-22 Compositions and methods for treating thymic stromal lymphopoietin (tslp)-mediated conditions

Country Status (9)

Country Link
EP (2) EP2350263A4 (en)
JP (4) JP5688370B2 (en)
CN (2) CN102256607B (en)
AU (2) AU2009308302B2 (en)
BR (2) BRPI0920430A2 (en)
CA (2) CA2741336A1 (en)
IL (2) IL212277A0 (en)
MX (2) MX2011004233A (en)
WO (2) WO2010048455A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6702949B2 (en) 1997-10-24 2004-03-09 Microdiffusion, Inc. Diffuser/emulsifier for aquaculture applications
WO2008052145A2 (en) 2006-10-25 2008-05-02 Revalesio Corporation Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
US8445546B2 (en) 2006-10-25 2013-05-21 Revalesio Corporation Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
EP2086668B1 (en) 2006-10-25 2016-11-16 Revalesio Corporation Mixing device and method
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
MX337862B (en) * 2008-04-28 2016-03-16 Revalesio Corp Compositions and methods for treating multiple sclerosis.
CA2723215A1 (en) 2008-05-01 2009-11-05 Revalesio Corporation Compositions and methods for treating digestive disorders
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
CA2798690A1 (en) 2010-05-07 2011-11-10 Revalesio Corporation Compositions and methods for enhancing physiological performance and recovery time
MX2013001636A (en) 2010-08-12 2013-05-01 Revalesio Corp Compositions and methods for treatment of taupathy
EA201391521A1 (en) * 2011-04-13 2014-03-31 Ревалезио Корпорейшн COMPOSITIONS AND METHODS FOR INHIBITING AND / OR MODULATING EFFECTOR T-CELLS PARTICIPATING IN THE INFLAMMATORY NEURODEGENERATIVE DISEASE
CN102250213B (en) * 2011-07-01 2012-11-07 中国药科大学 Matrix metalloproteinase-9 polypeptide inhibitor 3 and application thereof
CN102268069B (en) * 2011-07-01 2012-11-28 中国药科大学 Substrate metal prolease-9 polypeptide inhibitor 4 and application thereof
CN102268070B (en) * 2011-07-01 2012-11-28 中国药科大学 Substrate metal prolease-9 polypeptide inhibitor 2 and application thereof
KR101492435B1 (en) * 2012-12-28 2015-02-10 고려대학교 산학협력단 COMPOSITION FOR PREVENTING OR TREATING TSLP-MEDIATED DISEASES COMPRISING siRNA AGAINST HIF-1α AS AN ESSENTIAL COMPONENT
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
CN105477628B (en) * 2014-09-19 2021-04-30 山东蓝金生物工程有限公司 Anticancer composition and use thereof
CN106943593A (en) * 2017-03-24 2017-07-14 浙江中医药大学 Application of the anti-TSLP antibody in the chronic itch medicine of preventing and treating is prepared
WO2019005948A1 (en) * 2017-06-27 2019-01-03 Translational Sciences, Inc. Inhibition of vascular matrix metalloproteinase-9 to treat ischemic injury
CA3140952A1 (en) * 2019-05-17 2020-11-26 The Trustees Of The University Of Pennsylvania Methods and compositions for treating obesity and/or skin disorders
CN114887053A (en) * 2019-11-29 2022-08-12 康诺亚生物医药科技（成都）有限公司 Development and application of TSLP (total stress relaxation) related disease therapeutic agent

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232114A1 (en) * 2002-06-13 2003-12-18 Nikola Dekleva Method for liquid enrichment with oxygen and applications of enriched liquids
WO2004022098A1 (en) * 2002-09-09 2004-03-18 Borsos Ferenc Oxygen-enriched water, treated within a magnetic field and heavy water
US20070259032A1 (en) * 2006-05-01 2007-11-08 Corinne Bright Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury
WO2008052143A2 (en) * 2006-10-25 2008-05-02 Revalesio Corporation Mixing device and output fluids of same
WO2009055614A1 (en) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
WO2009134728A2 (en) * 2008-04-28 2009-11-05 Revalesio Corporation Compositions and methods for treating multiple sclerosis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69936453T2 (en) * 1998-07-28 2008-03-06 The Regents Of The University Of California, Oakland CODIGATING NUCLEIC ACIDS FOR A G-PROTEIN COUPLED RECEPTOR INVOLVED IN RECEPTOR TRANSDUCTION
CA2378880C (en) * 1999-07-21 2010-02-23 Omeros Medical Systems, Inc. Solutions and methods for inhibition of pain, inflammation and cartilage degradation
US20040235732A1 (en) * 2000-11-03 2004-11-25 Qun-Yong Zhou Method for modulating angiogenesis using prokineticin receptor antagonists
US20070077553A1 (en) * 2003-10-30 2007-04-05 Rosetta Genomics Bioinformatically detectable group of novel vaccinia regulatory genes and uses thereof
EP1599165A4 (en) * 2003-02-10 2010-09-08 Univ Jefferson The use of gcc ligands
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US7393924B2 (en) * 2004-01-06 2008-07-01 Franco Vitaliano Smart bio-nanoparticle elements
KR100583430B1 (en) * 2004-03-08 2006-05-24 양경숙 Wheel-exchangeable scooter
US20050249712A1 (en) * 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
WO2008005705A2 (en) * 2006-06-30 2008-01-10 Nucryst Pharmaceuticals Corp. Metal-containing formulations and methods of use
WO2008052145A2 (en) * 2006-10-25 2008-05-02 Revalesio Corporation Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
EP2083876A4 (en) * 2006-10-25 2012-09-19 Revalesio Corp Methods of wound care and treatment

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232114A1 (en) * 2002-06-13 2003-12-18 Nikola Dekleva Method for liquid enrichment with oxygen and applications of enriched liquids
WO2004022098A1 (en) * 2002-09-09 2004-03-18 Borsos Ferenc Oxygen-enriched water, treated within a magnetic field and heavy water
US20070259032A1 (en) * 2006-05-01 2007-11-08 Corinne Bright Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury
WO2008052143A2 (en) * 2006-10-25 2008-05-02 Revalesio Corporation Mixing device and output fluids of same
WO2009055614A1 (en) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
WO2009134728A2 (en) * 2008-04-28 2009-11-05 Revalesio Corporation Compositions and methods for treating multiple sclerosis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HANS LASSMANN: "Hypoxia-like tissue injury as a component of multiple sclerosis lesions", JOURNAL OF NEUROLOGICAL SCIENCES, ELSEVIER SCIENTIFIC PUBLISHING CO, AMSTERDAM, NL, vol. 206, no. 2, 15 February 2003 (2003-02-15), pages 187 - 191, XP008137062, ISSN: 0022-510X, DOI: 10.1016/S0022-510X(02)00421-5 *
See also references of WO2010048455A1 *

Also Published As

Publication number Publication date
JP5688371B2 (en) 2015-03-25
WO2010048425A1 (en) 2010-04-29
EP2364154A1 (en) 2011-09-14
AU2009308362A1 (en) 2010-04-29
AU2009308362B2 (en) 2016-02-04
JP2015044869A (en) 2015-03-12
IL212309A0 (en) 2011-06-30
CA2741341A1 (en) 2010-04-29
AU2009308302A1 (en) 2010-04-29
BRPI0920430A2 (en) 2019-09-24
CN102257130B (en) 2016-07-06
CN102256607B (en) 2014-11-05
IL212277A0 (en) 2011-06-30
AU2009308302B2 (en) 2016-01-21
CN102256607A (en) 2011-11-23
MX2011004235A (en) 2011-06-24
JP2012506451A (en) 2012-03-15
JP5688370B2 (en) 2015-03-25
CA2741336A1 (en) 2010-04-29
IL212309A (en) 2016-04-21
JP2015044868A (en) 2015-03-12
EP2350263A4 (en) 2013-07-03
EP2350263A1 (en) 2011-08-03
MX2011004233A (en) 2011-06-24
JP2012506453A (en) 2012-03-15
CN102257130A (en) 2011-11-23
WO2010048455A1 (en) 2010-04-29
BRPI0920201A2 (en) 2019-09-10
MX337035B (en) 2016-02-09

Similar Documents

Publication Publication Date Title
EP2364154A4 (en) Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions
HRP20182135T1 (en) Compositions and methods for treating ige-mediated disorders
IL205704A0 (en) Compositions and methods for treating purpura
EP2352517A4 (en) Methods and compositions for treating complement-associated disorders
PT2268612E (en) Arylsulfonamide-based matrix metalloprotease inhibitors
EP2029767A4 (en) Devices and methods for reducing matrix effects
EP2152891A4 (en) Genes and uses for plant enhancement
EP2214707A4 (en) Compositions and methods for treating inflammation
EP2170309A4 (en) Methods and compositions for treating disorders
PL3009148T3 (en) Compositions and methods for treating and diagnosing cancer
IL210097A0 (en) Compositions and methods for treating unfluenza
SI2520295T1 (en) Methods for preventing and treating mucositis
GB2466912B (en) Compositions and methods for treating lysosomal disorders
ZA200900140B (en) Methods and compositions for treating biofilms
EP2155249A4 (en) Compositions and methods for diagnosing and treating cancer
HUP0700369D0 (en) Pharmaceutical compositions and method for treating schizofrenia
GB0704718D0 (en) Compounds and methods for preventing and treating mucositis
EP2355818A4 (en) Methods and compositions for treating status epilepticus and seizures causing status epilepticus
EP2340254A4 (en) Compositions and methods for treating epilepsy
HK1129596A1 (en) Methods and compositions for treating disease
EP2142669A4 (en) Sirtuin based methods and compositions for treating b- catenin-related conditions
ZA201004212B (en) Method and composition for treating an alpha adrenoceptor-mediated condition
EP2094279A4 (en) Methods and compositions for treating influenza
EP2200627A4 (en) Methods and compositions for treating melanoma

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110520

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20130607

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/00 20060101AFI20130603BHEP

Ipc: A61K 31/573 20060101ALI20130603BHEP

Ipc: A61K 45/06 20060101ALI20130603BHEP

Ipc: A61K 33/00 20060101ALI20130603BHEP

Ipc: A61K 31/00 20060101ALI20130603BHEP

17Q First examination report despatched

Effective date: 20150828

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170503